MAP Pharmaceuticals, Inc. - Common Stock

("Allergan 4Q Net Falls 6.3% On Higher R&D Costs; Margins Improve," at 9:41 am EST, misstated the earnings change direction in the headline and first and fourth paragraphs.

MAP Pharmaceuticals (NASDAQ:MAPP) is one of today's biggest movers, down 2.3% to $13.86. The S&P is currently trading 0.7% lower to 1307 and the Dow Jones Industrial Average is trading 0.7% lower to 12578.

In the research for my most recent piece on Biotech Buyouts I uncovered a list of attractive smaller bio/pharma companies that were developing compelling new drugs.

MAP Pharmaceuticals (NASDAQ:MAPP) is a company whose shares are active, trading 1.7% higher to $14.33. The S&P is trading fractionally lower to 1323 and the Dow is trading fractionally higher to 12780.

Looking for ideas on how to find potentially undervalued stocks? If so, you may be interested in this list. We ran a screen on high-growth stocks, with projected 5-year EPS growth above 20%, for those trading at the steepest discounts to even their ...